Compare SMTI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMTI | LUNG |
|---|---|---|
| Founded | 1982 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.6M | 57.9M |
| IPO Year | 2008 | 2020 |
| Metric | SMTI | LUNG |
|---|---|---|
| Price | $22.85 | $1.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $34.00 | $5.38 |
| AVG Volume (30 Days) | 37.9K | ★ 520.2K |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ 0.05 | N/A |
| Revenue | $15,586,976.00 | ★ $90,497,000.00 |
| Revenue This Year | $17.31 | $2.48 |
| Revenue Next Year | $12.48 | $18.46 |
| P/E Ratio | $476.50 | ★ N/A |
| Revenue Growth | ★ 32.47 | 8.01 |
| 52 Week Low | $16.05 | $1.13 |
| 52 Week High | $35.70 | $3.88 |
| Indicator | SMTI | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 65.71 | 66.44 |
| Support Level | $22.60 | $1.51 |
| Resistance Level | $25.14 | $1.64 |
| Average True Range (ATR) | 1.48 | 0.09 |
| MACD | 0.38 | 0.04 |
| Stochastic Oscillator | 79.73 | 82.34 |
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.